Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Purpose TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study aims to investigate the clinical and histopathological characteristics of patients with microphthalmia t...

书目详细资料
Main Authors:	Joohyun Hong, Ghee Young Kwon, Minyong Kang, Seong Il Seo, Se Hoon Park
格式:	文件
语言:	English
出版:	Korean Urological Oncology Society 2024-03-01
丛编:	Journal of Urologic Oncology
主题:	-rearranged -altered renal cell carcinoma tyrosine kinase inhibitors immune checkpoint inhibitors
在线阅读:	http://www.e-juo.org/upload/pdf/juo-234600660033.pdf

相似书籍

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
由: Huang JT, et al.
出版: (2022-11-01)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
由: Pan X, et al.
出版: (2023-06-01)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
由: Fei Yang, et al.
出版: (2022-01-01)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
由: Hongyu Pan, et al.
出版: (2025-03-01)

Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors
由: A. Yu. Goryainova, et al.
出版: (2021-12-01)

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
由: Gao B, et al.
出版: (2023-12-01)

Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors
由: Ning Luo, et al.
出版: (2023-08-01)

Additive toxicity arising from combined use of immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with renal or endometrial carcinoma: Protocol for a rapid systematic review
由: Shannon E. Kelly, et al.
出版: (2024-06-01)

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study
由: Guosheng Yuan, et al.
出版: (2024-03-01)

Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
由: Sang Youn Hwang, et al.
出版: (2023-11-01)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
由: Christopher Kwok, et al.
出版: (2023-07-01)

Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
由: Junfeng Bu, et al.
出版: (2025-02-01)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
由: Karam Khaddour, et al.
出版: (2020-10-01)

Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors
由: Yiwan Guo, et al.
出版: (2024-01-01)

Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis
由: David O’Reilly, et al.
出版: (2024-07-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
由: Yifan Zhang, et al.
出版: (2024-06-01)

Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors
由: Shasha Sun, et al.
出版: (2024-12-01)

Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
由: Emmy D. G. Fleuren, et al.
出版: (2021-11-01)

Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report
由: Jian Wang, et al.
出版: (2024-12-01)

Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
由: Changjie Du, et al.
出版: (2024-05-01)

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
由: Renguo Guan, et al.
出版: (2022-09-01)

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
由: Yuhang Chen, et al.
出版: (2024-12-01)

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
由: Qiao Ke, et al.
出版: (2022-05-01)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
由: Ling Peng, et al.
出版: (2022-04-01)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
由: Yue Chen, et al.
出版: (2022-06-01)

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization
由: Halil Ibrahim Onder, et al.
出版: (2014-04-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
由: Ichiro Yamauchi, et al.
出版: (2025-01-01)

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
由: Daniela R. Montagna, et al.
出版: (2022-08-01)

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
由: Pottayil G. Sasikumar, et al.
出版: (2020-12-01)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
由: Ryo Ariyasu, MD, et al.
出版: (2023-06-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
由: Yi-fan Chen, et al.
出版: (2011-12-01)

A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study
由: Kexue Deng, et al.
出版: (2022-09-01)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
由: Jingyang Su, et al.
出版: (2024-04-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
由: Eva Zhang, et al.
出版: (2021-05-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
由: CHEN Shuangqing, et al.
出版: (2022-10-01)

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature
由: Qi Zhu, et al.
出版: (2022-05-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
由: Hanping Wang, et al.
出版: (2020-01-01)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
由: Yuanquan Yang, et al.
出版: (2022-08-01)

Fatal Case of Immune-Related Myocarditis and Myositis Due to Treatment with Immune Checkpoint and Tyrosine Kinase Inhibitors
由: João Queirós Coelho, et al.
出版: (2024-10-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
由: Hor-Yue Tan, et al.
出版: (2018-02-01)